Dermatitis, Eczema, Vitiligo and Psoriasis
A randomized, double-blind, placebo-controlled, multicenter trial with the aim to investigate whether daily treatment with Polypodium leucotomos extract would reduce the use of topical corticosteroids in children and adolescents with atopic dermatitis.
While the study did not find a reduction in the percentage of days on which topical corticosteroids were used (11% [12%] vs 12% [11%] for placebo), it did find a significant reduction in oral histamine use (4.5% vs 13.6% in the placebo group).6
The study concluded that Long-term treatment with Polypodium leucotomos extract has benefits for children and adolescents with atopic dermatitis who require pharmacologic treatment to reduce inflammation and relieve itching. 6
A study in 1974 first isolated a triterpenoid glycoside from the mashed and dried rhizomes and was named Calagualine in honor of the common name of Polypodium Leucotomos, Calaguala.
The extract (20 capsules with a concentration not specified) and a placebo were given to 36 patients (age 6-63) suffering from Psoriasis for as long as 24 years and as short as one month.
The results showed a significant improvement in clinical signs of Psoriasis. 7
One study found that using 0.25mg/kg of Polypodium Leukotomos (PL) hydro soluble extract (intramuscular injections) for 7 days prior to surgery, the PL was able to normalize a trauma-induced shift in T-cell morphology and attenuate changes in select cytokines (IL-6 and IL-12, but not IL-1, 2, or 4). that are seen as indicative of this shift of T-cell morphology 9
The same effects have also been noted in response to Fasciola hepatica antigen, which triggers a similar Th2 immune response.10
In 2007 a study investigated if PLE improves NB-UVB-induced re-pigmentation in Vitiligo patients.
50 patients suffering from Vitiligo randomly received 250mg of PLE or a placebo three times daily, combined with NB-UVB twice a week for 25-26 weeks.
As a result, re-pigmentation was higher in the PLE group than the placebo in the head and neck area (44% vs 27%) for the trunk it was 6%, hand, and feet 5% and extremities 4%. Patients attending more than 80% of NB-UVB sessions, showed increased re-pigmentation in the head and neck areas (50% vs 19% of the placebo group). 7